Introduction: Assessment of Human papillomavirus (HPV) prevalence and genotype distribution is 28 important for monitoring the impact of prophylactic HPV vaccination. This study aimed to 29 demonstrate the HPV genotypes predominating in pre-malignant and cervical cancers in Northern 30 Ireland (NI) before the vaccination campaign has effect.
156
HPV types identified by the Roche linear array are shown in Table 3. 8
RESULTS

182
In total, 2,303 samples were received between April 2011 and February 2013. Figure 1 is a flow 183 diagram providing justification for the selection of study samples. Exclusions included 58 samples 184 that were not tested due to overrepresentation in the low-grade dyskaryosis groups, a further 200 185 were excluded at the post-analytical phase of the study due to insufficient tissue remaining for 186 molecular analysis. 218 samples were also excluded as they were not SCC, AC or CIN I-III pathologies.
187
A total of 1,827 eligible samples were included for analysis, the majority of which were acquired 188 through large loop excisions of the transformation zone (64.8%) or punch biopsies (34.2%).
190
Prevalence of HPV infection:
191
In total, 1,243/1,827 samples (68.0%) tested positive for HPV, with the majority 1,183/1,827 (64.8%)
192
having HR-HPV infection. A total of 584/1,827 (32.0%) of samples were HPV negative, 37.4% were 193 positive for HPV-16 (n=684) and 5.1% for HPV-18 DNA (n=93). Figure 2 
217
Age-specific prevalence for HPV infection:
218
The pathological distribution of samples by five-year age group is shown in Table 4 . The mean age of 219 women included in the study was 32 years (range 16-93 years, standard deviation (SD) 9.4 years) and 220 significantly differed between histopathological groups (P <0.001). In total, 375 samples were from Table 4 .
225
The number of HPV genotypes decreased with increasing age, with just over half (51.0%) of all HPV 226 infections found in tissue from women aged between 25-29 years, 
271
In an examination of FFPE tissue from more than 6,000 women from 17 European countries using 272 the SPF10-LiPA25 assay, including data from neighbouring Scotland, Ireland and Wales, Tjalma et al 273 found HPV-16 was the most frequent HPV type detected in both CIN and invasive cervical cancer 274 [Tjalma et al, 2013] . HPV-16 and/ or HPV-18 prevalence (among HPV positive cases) was reported as 275 45.8% in CIN II and 67.3% in CIN III cases [Tjalma et al, 2013] , slightly higher than the current study.
276
The authors reported 33, 35, 51, 52, 58 and 68 as the most frequently detected genotypes 277 in women with high-grade CIN lesions. Apart from HPV-16, we similarly found that HPV-18, 31, 33, 278 45, 51 and 52 were the most common genotypes identified in high grade lesions. Building on 279 previous meta-analyses of type-specific HPV prevalence worldwide by specific grades of cervical 280 disease [Clifford et al, 2003 [Clifford et al, , 2005 Smith et al, 2007; Li et al, 2011] Guan et al in a further meta-281 analysis of 423 studies (144 of which were from Europe) using PCR assays based on various primers 282 among cell or biopsy/tissue cervical diagnoses also showed an increasing HPV prevalence with 12 grades [Guan et al, 2012] . The prevalence (including HPV negative cases in the denominator) of HPVvariation which may have arisen from methodological differences in HPV detection techniques. The 
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There were only 14 cases of AC included in the current investigation, and therefore our study is likely 295 underpowered to investigate HPV prevalence in this subgroup. Of note however, HPV-18 was the 296 most common HPV type in AC cases with a prevalence of 42.9% in the current study, akin to a recent 
326
The principal strength of this study is its size and population-based design. The study was able to 327 report the identification of high and low-risk HPV genotypes as well as the prevalence of multiple 328 HPV infections. When comparing the HPV prevalence between countries it is important to consider 329 that variations in HPV positivity may be explained by differences in the quality and type of samples 7 (10.9) 5 (7.8) 7 (10.9) 3 (4.7) 1 (1.6) 6 (9.4) 64 (100.0) AC 42 (16; 23-73) 1 (7.1) 2 (14.3) 3 (21.4) 3 (21.4) 0 (0.0) 1 (7.1) 0 (0.0) 1 (7.1) 1 (7.1) 2 (14.3) 14 (100.0) TOTAL n (%) 375 (20.5) 529 (28.9) 358 (19.6) 222 (12.2) 151 (8.3) 92 (5.0) 49 (2.7) 28 (1.5) 9 (0.5) 14 (0.8) 1,827 (100.0) CIN = Cervical Intraepithelial Neoplasia (grades I-III), SCC = Squamous Cell Carcinoma, AC= Adenocarcinoma ±SD = Standard deviation N.B.: Please note that certain pathological groups were overrepresented in this study, so the proportions above may not be a true reflection of the distribution of cervical pathologies within each age category in Northern Ireland.
